Advancing Women’s Heart Health Through Prevention and Rapid Diagnosis
Early intervention based on accurate diagnosis of both metabolic risk factors and acute cardiac events…
Advancing Women’s Heart Health Through Prevention and Rapid Diagnosis
Early intervention based on accurate diagnosis of both metabolic risk factors and acute cardiac events could help make the difference between life and death for women. The post Advancing Women’s Heart Health Through Prevention and Rapid Diagnosis appeared first on MedCity News.
GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs
GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers. The post GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs appeared first on MedCity News.
When “Paying Correctly” Means Paying Nothing: How to Make Medicare Advantage Accountable
By FRANK LEAHY This is the second of two pieces. The first told the story of “Rick,” a 77-year-old Humana Medicare Advantage member who nearly lost his sight in a months-long runaround over a retinal detachment. This one asks what his case reveals, and what would help fix it. The runaround was exhausting – the…
Oracle Health Execs Subpoenaed After VA Contract Costs Nearly Triple
The House VA Committee voted 19-0 to subpoena Oracle Health executives Larry Ellison and Mike Sicilia after learning the VA’s EHR contract ballooned from $10 billion to $27 billion — despite Oracle’s promise to Congress that it would absorb any costs beyond the original cap. The post Oracle Health Execs Subpoenaed After VA Contract Costs…
FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease
Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner. The post FDA Approves Ionis Pharma Drug, the First for…
Bringing Ski Patrol Lessons to Healthtech Entrepreneurship
Three things ski patrol can teach about building a business The post Bringing Ski Patrol Lessons to Healthtech Entrepreneurship appeared first on MedCity News.
Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem
Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs. The post Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem appeared first on MedCity News.
7 Hospital Mergers from Summer 2026
A roundup of the seven most notable hospital mergers and acquisitions announced or completed this summer, including Prisma Health’s acquisition of Erlanger Health and Sanford Health’s purchase of North Memorial Health The post 7 Hospital Mergers from Summer 2026 appeared first on MedCity News.
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder
Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed…
Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands
This shift is not about replacing clinical care with tradition. It is about recognizing that healing in Native communities has always been deeply connected to culture. The post Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands appeared first on MedCity News.
